The smartwatch market generated approximately 38.6 billion US dollars in revenue globally in 2022, and growth is expected to continue. Over a hundred of these devices, ranging from AI ultrasounds to smart sleep trackers and ECG watches, have been tried and tested by the author. His “7+1” recommendations are listed here.

The Food and Drug Administration has approved digital therapeutics, but insurance coverage has remained a problem. Some businesses have pushed for patient pharmacy benefits to pay for their software-based therapies, but AppliedVR is going in a different direction. A new HCPCS (Healthcare Common Procedure Coding System) code that describes the company’s treatment as a virtual reality cognitive behavioral therapy device with pre-programmed therapy software was granted by CMS to the company. The program complied with all five criteria set forth by CMS to qualify as durable medical equipment.

Medtronic is collaborating with Nvidia on developing means to allow AI to run on its devices. The solution will use Nvidia chips on Medtronic devices and an AI layer that would allow doctors to create their own algorithms to run on the machines. The first will be implemented on the GI Genius endoscopy module. Medtronic hopes the strategy will mean that millions of users around the globe will be contributing to making their devices more capable and flexible for the diversity of real-world clinic challenges.

The convenience and comfort telehealth delivers for managing nonurgent and routine care for mental health, chronic disease, or pain is too good to revert back to always in-person appointments. And telehealth is changing the way providers compete — every system is now in direct competition with an expanded list of players. It’s also changing the way consumers select providers. For example, they are moving their care to those that can provide their entire health history online.

Five-hundred thirty-five (535) digitalized biopsies were graded against three standard indexes. A neural network was trained to distinguish remission from activity. The model predicted endoscopic-verified remission or activity with approximately 80% accuracy.

Long-term outcomes of lifestyle interventions to promote weight maintenance — the current first-line management for patients with NAFLD — are often unsatisfactory. DTx can overcome the drawbacks of traditional lifestyle treatments through telecare medical services. At the same time, implementing DTx introduces a different level of self-management motivation for patients, greatly improving the treatment adherence and therapeutic effect among NAFLD patients.